๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Chengdu 44 Chongqing 2 Guiyang 2 Wuhan 2 Sichuan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Chengdu44 Chongqing2 Guiyang2 Wuhan2 Sichuan2
All 11 locations
Target enrolment
to

Trials with a site in Chengdu

44 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
NCT07258147Lung Cancer (SCLC)
Sichuan University
Phase 2
30
Chengdu
2026-10-31
Recruiting
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
NCT07767630Neuroblastoma (NB)
Sichuan University
Phase EARLY_PHASE1
10
Chengdu
2026-07-21
Not yet open
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study
NCT07665697Neoplasms, Drug Therapy, Immune Checkpoint Inhibitors (ICIs)
Sichuan University
Observational
500
Chengdu
2026-06-30
Not yet open
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
NCT07692048NSCLC
Sichuan University
Phase 1
21
Chengdu
2026-06-30
Not yet open
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
NCT07637786Advanced Pancreatic Adenocarcinoma
Sichuan University
Phase 1
9
Chengdu
2026-06-20
Recruiting
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
NCT07519486Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
118
Chengdu
2026-04
Not yet open
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
NCT07374250Gastric Cancer, RCT
Sichuan University
Phase 2
154
Chengdu
2026-02-01
Not yet open
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
NCT07154108Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Sichuan University
Phase 1
40
Chengdu
2025-09-01
Not yet open
Lateral Positioning for Extubation After Adenotonsillectomy
NCT07108218Perioperative Respiratory Adverse Events, Adenoidectomy, Tonsillectomy, Children
Sichuan University
Not applicable
350
Chengdu
2025-08-20
Recruiting
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
NCT07061704Esophageal Cancer
Sichuan University
Phase 1/2
40
Chengdu
2025-08-01
Recruiting
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
NCT07067346Neuroblastoma
Sichuan University
Phase EARLY_PHASE1
10
Chengdu
2025-07-18
Recruiting
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage โ…กA-โ…ขB Non-small Cell Lung Cancer
NCT06877299Lung Cancer, Non-small Cell Lung Cancer
Sichuan University
Phase 2
30
Chengdu
2025-07-04
Recruiting
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
NCT06951464Non-Small Cell Lung Cancer
Sichuan University
Phase 2
40
Chengdu
2025-06-25
Recruiting
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
NCT07004244Malignant Tumors
Sichuan University
Phase 1
20
Chengdu
2025-06-05
Not yet open
NAD+ Supplement๏ผˆNMN๏ผ‰With Radioimmunotherapy in Advanced NSCLC
NCT06966583Solid Tumor, Non Small Cell Lung Cancer
Sichuan University
Phase 1
20
Chengdu
2025-05-01
Recruiting
Phase I Clinical Study of ฮฑ-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
NCT06348797Small Cell Lung Cancer Extensive Stage
Sichuan University
Phase 1
30
Chengdu
2025-04-03
Recruiting
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale๏ผˆPREDICT-PFO Trial๏ผ‰
NCT06863350Epilepsy (treatment Refractory)
Sichuan University
Not applicable
180
Chengdu
2025-02-28
Recruiting
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
NCT06769971Small Cell Lung Cancer
Sichuan University
Phase 2
80
Chengdu
2025-02-01
Recruiting
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
NCT06769295Lung Cancer, Non-Small Cell
Sichuan University
Phase 2
28
Chengdu
2025-02-01
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Recruiting
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
NCT06675201Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
Sichuan University
Phase 2
165
Chengdu
2024-10-01
Not yet open
The Effect of Aromatherapy for First Dental Visit Patients
NCT06598904Dental Anxiety
Sichuan University
Not applicable
120
Chengdu
2024-09-20
Recruiting
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
NCT06446726Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2
30
Chengdu
2024-06-30
Active, closed
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
NCT06477523SCLC, Extensive Stage
Sichuan University
Phase 1/2
57
Chengdu
2024-05-16
Not yet open
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
NCT06346808Pancreatic Cancer
Sichuan University
Phase 1
20
Chengdu
2024-05-01
Recruiting
Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in Adults
NCT06347679Dental Anxiety
Sichuan University
Not applicable
120
Chengdu
2024-05-01
Recruiting
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
NCT06431685NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
Sichuan University
Phase 1
10
Chengdu
2024-04-25
Recruiting
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
NCT06349837Solid Tumor
Sichuan University
Phase 1
24
Chengdu
2024-04-18
Recruiting
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
NCT06217757Lung Cancer, Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 1/2
45
Chengdu
2024-04-18
Recruiting
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
NCT06344156Pancreatic Cancer, Adjuvant Therapy
Sichuan University
Phase 1
43
Chengdu
2024-04-01
Recruiting
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
NCT06121505Lung Squamous Cell Carcinoma
Sichuan University
Phase 2
114
Chongqing, Guiyang, Wuhan, Chengdu, Nanchong
2024-03-01
Recruiting
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure๏ผšPhase I/II
NCT06195189Non Small Cell Lung Cancer
Sichuan University
Phase 1/2
40
Chengdu
2024-02-29
Recruiting
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
NCT06084286Advanced Solid Tumor
Sichuan University
Phase 1
29
Chengdu
2024-01-01
Not yet open
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
NCT06075238Leukemia, Lymphoid
Sichuan University
Phase 2
68
Chengdu
2023-10-01
Not yet open
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
NCT06075225GVHD, Acute Stem Cell Transplant Complications
Sichuan University
Phase 2
62
Chengdu
2023-10-01
Recruiting
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
NCT06603402Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy
Sichuan University
Phase 2
41
Chengdu
2023-08-24
Active, closed
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Recruiting
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
NCT05477927Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises, Leptomeningeal Metastases
Sichuan University
Phase 1
40
Chengdu
2023-02-15
Recruiting
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
NCT05682755Leukemia, Myeloid, Acute
Sichuan University
Phase 1/2
77
Chengdu
2022-12-22
Recruiting
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
NCT07014943Primary Central Nervous System Lymphoma (PCNSL)
Sichuan University
Phase 2
34
Chengdu
2022-01-01
Active, closed
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NCT05615142NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor
Sichuan University
Phase 1
9
Chengdu
2021-12-15
Recruiting
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
NCT04684459Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant, HER2 Positive Malignancies
Sichuan University
Phase EARLY_PHASE1
18
Chengdu
2021-03-12
Recruiting
Personalized DC Vaccine for Postoperative Cancer
NCT04147078Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
Sichuan University
Phase 1
80
Chengdu
2019-06-01
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Chengdu that also match the filters currently applied.

How many clinical trials are recruiting in Chengdu?

28 of the 44 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 13 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chengdu), 44 studies
PhaseStudiesRecruitingShare
Phase 2161136.4%
Phase 114831.8%
Phase 1/25411.4%
Not applicable429.1%
Phase EARLY_PHASE1336.8%
Observational204.5%

Most active sponsors

Lead sponsors with the most studies (Chengdu)
Lead sponsorStudiesRecruiting
Sichuan University4428
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.